Company news
Silo Pharma, Inc. news in 2025
Silo Pharma, Inc.'s news releases, calls and decks from 2025, newest first.
Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
December 29, 2025
Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
November 16, 2025
Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
October 29, 2025
Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
October 28, 2025
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
October 22, 2025
Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth
October 9, 2025
Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company’s Commitment to Multi-Chain Growth
October 7, 2025
Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
October 5, 2025
Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
September 30, 2025
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
September 29, 2025
Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
September 28, 2025
Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
September 22, 2025
Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
September 15, 2025
Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
September 8, 2025
Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
September 2, 2025
Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
August 21, 2025
Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
August 19, 2025
Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
August 18, 2025
Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
August 4, 2025
Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
July 15, 2025
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
July 6, 2025
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
June 24, 2025
Silo Pharma Enters into Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
June 24, 2025
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
June 10, 2025
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
June 4, 2025
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
May 20, 2025
Silo Pharma Announces Closing of $2 Million Public Offering
May 15, 2025
Silo Pharma Announces Pricing of $2 Million Public Offering
May 14, 2025
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
May 13, 2025
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
May 13, 2025
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
April 30, 2025
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
April 29, 2025
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug
April 28, 2025
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
April 27, 2025
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
March 25, 2025
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
February 25, 2025
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
February 17, 2025
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
February 10, 2025
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
January 21, 2025
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
January 7, 2025
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
January 1, 2025
Decks in 2025
- Investor Presentation (March 2025)
Investor deck · 17 slides · Mar 10, 2025
- Investor Presentation (March 2025)
Investor deck · 18 slides · March 2025